SCHEMBL6538147

SCHEMBL6538147

NC(=O)N1CCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Squamolone SCHEMBL1051735 0.85
Squamolone SCHEMBL28367081 0.83 LMNA (0.57)
SCHEMBL4702017 0.83 LMNA (0.52)
SCHEMBL1424272 0.81 LMNA (0.50)
SCHEMBL15233814 0.78 LMNA (0.44)
SCHEMBL17224707 0.77
SCHEMBL2225143 0.76
SCHEMBL14140164 0.74
SCHEMBL4728242 0.74
SCHEMBL12104208 0.73 LMNA (0.62)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170218353-A1 Ligand-Directed Covalent Modification of Protein CELGENE CAR LLC (BM) 2017-08-03 US disclosed
US-20170218353-A1 Ligand-Directed Covalent Modification of Protein CELGENE CAR LLC (BM) 2017-08-03 US disclosed
US-20110269244-A1 LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN CELGENE CAR LLC (BM) 2011-11-03 US disclosed
US-20110269244-A1 LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN CELGENE CAR LLC (BM) 2011-11-03 US disclosed
EP-0595557-B1 New substituted azetidinones as anti-inflammatory and antidegenerative agents MERCK & CO INC (US) 2004-06-30 EP disclosed
EP-0755262-A4 COMPOSITION FOR THE TREATMENT OF LUNG DISEASE MERCK & CO INC (US) 1997-05-07 EP disclosed
EP-0755262-A1 COMPOSITION FOR THE TREATMENT OF LUNG DISEASE MERCK & CO. INC. (US) 1997-01-29 EP disclosed
CN-1068815-A Be used as the new substituted azetidinone of anti-inflammatory and antidegenerative agent MERCK & CO INC (US) 1993-02-10 CN disclosed